The exchange offer's completion confirms massive dilution and a higher-cost secured debt structure, which is negative for common equity. Expect continued downward pressure on GOSS shares as the market absorbs the new equity. Monitor the July 14 special meeting for any additional financing or restructuring steps.
Price Chart
Executive Summary
Gossamer Bio announced final tender results for its exchange offer, with $181.1M of its 5.00% convertible notes (90.5% of the total) tendered and exchanged for a mix of new 7.50% secured notes, up to 317.6M common shares (or prefunded warrants), and warrants. The remaining $18.9M in notes will stay outstanding with substantially all restrictive covenants eliminated. The massive equity issuance is highly dilutive to existing common shareholders.
Key Facts
- $181,052,000 aggregate principal amount of 5.00% Convertible Senior Notes due 2027 were validly tendered and exchanged
- $18,948,000 in aggregate principal amount of the existing notes will remain outstanding
- Up to $72.0 million in new 7.50% Convertible Senior Secured First Lien Notes due 2030 were issued
- Up to 317,647,058 shares of common stock (or prefunded warrants) were issued as part of the exchange
- Early settlement occurred on June 4, 2026, and a supplemental indenture eliminated substantially all restrictive covenants and certain events of default on the existing notes
- A special meeting of stockholders is scheduled for July 14, 2026 to consider related proposals
Financial Impact
Massive dilution: up to 317.6M new shares relative to an $82M market cap; interest cost increases from 5% to 7.5% on $72M of new secured debt; remaining $18.9M notes have weakened covenants
Risk Factors
- Further dilution if additional equity or convertible offerings are needed
- Inability to fund operations or clinical trials (seralutinib) given ongoing cash burn
- Potential for further debt restructuring or distressed exchange if pipeline milestones are missed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001728117-26-000054 |
| Document: goss-20260617xexx991xprfin.htm | 0001728117-26-000054 |
| Document: 0001728117-26-000054-index-headers.html | 0001728117-26-000054 |
| Document: 0001728117-26-000054-index.html | 0001728117-26-000054 |
| Document: 0001728117-26-000054.txt | 0001728117-26-000054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | SC 13D/A | $9.31 | awaiting T+20 | — | $9.15 (+1.72%) |
Sep 28, 2026 27d ago | SC 13D/A | $11.58 | awaiting T+20 | — | $9.15 (+20.98%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.69 $9.58 | ▼ −18.05% | ▼ −17.49% | $9.15 (−21.73%) |
Sep 16, 2026 5w ago | 8-K | $11.94 $8.89 | ▼ −25.54% | ▼ −26.75% | $9.15 (−23.37%) |
Sep 11, 2026 6w ago | 8-K | $10.73 $9.31 | ▲ +13.23% | ▲ +15.10% | $9.15 (+14.73%) |
Sep 9, 2026 6w ago | 8-K | $0.1597 $0.1273 | ▼ −20.32% | ▼ −22.26% | $9.15 (+5629.49%) |
Aug 21, 2026 9w ago | 8-K | $0.1547 $0.1410 | ▲ +8.86% | ▲ +9.87% | $9.15 (−5814.67%) |
Aug 13, 2026 10w ago | 8-K | $0.1542 $0.1337 | ▼ −13.26% | ▼ −11.27% | $9.15 (+5833.85%) |
Jul 1, 2026 16w ago | 8-K | $0.1677 $0.1783 | ▼ −6.32% | ▼ −6.87% | $9.15 (−5356.17%) |
Jun 17, 2026 18w ago | 8-K | $0.1790 $0.1701 | ▲ +4.97% | ▲ +5.29% | $9.15 (−5011.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers